Polypharmacy is one of the major concerns in the management of diabetic patients with comorbidities as it results in medication non-adherence, drug-drug interactions, drug-disease interactions, and adverse drug events. Evidence suggests that careful assessment of negative outcomes of polypharmacy and implementation of appropriate insulin-based therapy can significantly help in the management of diabetes and major comorbidities. Lupin has organized an interactive Webinar on 3rd June 2018 from 11:00 AM onwards.
In this webinar, Guest of honor Dr. Vivian Andrew Fonseca and renowned Endocrinologists from India will share their viewpoints on the topic of “Can Insulin Sustain The Onslaught Of Polypharmacy In Type 2 Diabetes?" We invite you to submit your question which will be answered by the experts from the field of diabetology.
